Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval
Regenxbio says Duchenne gene therapy succeeded in clinical trial | STAT
REGENXBIO to push for accelerated approval of DMD gene therapy
Regenxbio posts mixed Phase III data on RGX-202 | The Pharmaletter
Regenxbio Releases Q1 2026 Financial Results - Alphastreet
Regenxbio slides after late-stage trial data for Duchenne therapy
Regenxbio Gene Therapy Hits 93% Expression in Trial, Challenging Rival
Regenxbio Shares Rise After Positive Duchenne Trial Results
Regenxbio reaps pivotal win for Duchenne gene therapy
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
Regenxbio stock gains 4% on Duchenne trial win despite earnings miss By ...
Will FDA show Affinity for fast yes to Regenxbio in DMD? | BioWorld
REGENXBIO slumps after serious side effects mar Duchenne gene therapy ...
REGENXBIO ($RGNX) Releases Q1 2026 Earnings | Quiver Quantitative
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Stock Movers: Cisco, Ford, Regenxbio - Bloomberg
REGENXBIO Inc.: REGENXBIO Reports First Quarter 2026 Financial Results ...
Brain tumor prompts FDA hold for 2 Regenxbio gene therapies
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays ...
Regenxbio says FDA extends review date for Hunter syndrome drug
REGENXBIO falls after FDA clinical hold (RGNX:NASDAQ) | Seeking Alpha
AbbVie & Regenxbio Update ABBV-RGX-314 Program | OBN
Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic ...
Regenxbio Inc: доходы, прибыль оказались ниже прогнозов в Q1 От ...
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported And ...
The past five years for REGENXBIO (NASDAQ:RGNX) investors has not been ...
Акции Regenxbio обвалились вопреки успешным данным по генной терапии ...
Regenxbio Inc: EPS verfehlt Schätzungen um 0,38 $ - Umsatz schlechter ...
FDA hits Regenxbio with CRL for Hunter syndrome gene therapy ...
Regenxbio guadagna il 4% grazie ai risultati sulla distrofia di ...
REGENXBIO Receives FDA Fast Track Designation for its Novel Gene ...
REGENXBIO Announces Positive Long-Term Functional Outcomes in Duchenne ...
REGENXBIO DMD Gene Therapy Shows Superior Results in Key Scientific ...
RegenXBio gets FDA support for accelerated gene therapy filing
RegenxBio receives OK to start clinical trials for wet age-related ...
Chardan Capital Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX ...
FDA hits pause on Regenxbio gene therapies after child’s brain tumor ...
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY ...
Regenxbio Expands Build-to-Suit Lease in Rockville Biotech Hub
REGENXBIO and AbbVie Advance Sura-Vec for Diabetic Retinopathy
Regenxbio reports positive interim data from Phase 1/2 microdystrophin ...
FDA Suspends Regenxbio Gene Therapy Trials After Brain Tumor Case | The ...
RegenxBio kicks off late-stage clinical trial with AbbVie for eye ...
REGENXBIO will participate in upcoming investor conferences. Learn more ...
REGENXBIO (Nasdaq: RGNX)Gene Therapy Portfolio, Stock and Financial ...
REGENXBIO Manufacturing Innovation Center Opens in Rockville ...
Regenxbio Reports Positive Biomarker Data From Affinity Duchenne Trial ...
Rockville’s RegenxBio expands roles of 2 C-suite executives ...
REGENXBIO Shares Fall as FDA Places MPS Trials on Clinical Hold
REGENXBIO Reports Q3 2025 Financial and Operational Progress - TipRanks.com
REGENXBIO Announces Closing of Eye Care Collaboration Agreement with ...
Regenxbio could be a gene therapy pioneer with multiple ways to win in ...
Regenxbio stock drops on FDA setback for RGX-121 gene therapy (RGNX ...
REGENXBIO (RGNX) FDA Approvals, PDUFA Dates & Drug Alerts 2026
RegenxBio
REGENXBIO Reports First Quarter 2025 Financial Results and Recent ...
RegenxBio Bets Its Gene Therapy Technology Provides Competitive Edge
REGENXBIO Initiates Pivotal Phase of AFFINITY DUCHENNE® Trial of RGX ...
REGENXBIO announces second pivotal trial, ASCENT, in RGX-314 clinical ...
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional ...
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon ...
REGENXBIO Inc. on LinkedIn: REGENXBIO was happy to have attended the ...
REGENXBIO Inc. (RGNX): Business Model Canvas – DCFmodeling.com
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include ...
AbbVie Expands Ophthalmology Pipeline with Regenxbio Gene Therapy Deal
REGENXBIO Inc. on LinkedIn: REGENXBIO will participate in the Goldman ...
REGENXBIO by EwingCole - Architizer
REGENXBIO ANNOUNCES PHASE I/II TRIAL OF RGX-202, A NOVEL GENE THERAPY ...
RegenxBio to globally expand pivotal trials for wet AMD gene therapy
FDA Fast Tracks Regenxbio Gene Therapy
Regenxbio provides updates on its AVV gene therapy pipeline
With new data, RegenxBio advances plan for Duchenne gene therapy
Regenxbio starts pivotal study for DMD gene therapy
REGENXBIO FDA Review of Hunter Syndrome Gene Therapy Extended to 2026 ...
Regenxbio to Trial Duchenne Muscular Dystrophy Gene Therapy
REGENXBIO Unveils Promising Phase I/II Trial Results for Gene Therapy ...
CureDuchenne Webinar - An Introduction to REGENXBIO and RGX-202 ...
REGENXBIO Study in The Lancet: Single-Dose Gene Therapy ABBV-RGX-314 ...
Regenxbio's Duchenne gene therapy clears phase 3 hurdle | pharmaphorum
Splicing Patent Eligibility: The Federal Circuit Restores § 101 ...
Regenxbio’s muscle disorder therapy meets main goal in late-stage study ...
BeOne, Diamantas, CREATE, Regenxbio: Readout Newsletter
Regenxbio股价上涨4%，杜氏肌营养不良症试验获捷报，但业绩未达预期 提供者 Investing.com
Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC ...
RGNX Q1 2023 Earnings Report on 5/3/2023
Regenxbio's FDA Review Extension for RGX-121 and Its Implications for ...
REGENXBIO: FDA puts RGX-111, RGX-121 trials on hold | RGNX Stock News
FDA Delays Decision on Regenxbio's Hunter Syndrome Gene Therapy: What ...
New Positive Functional Data From The RGX-202 Affinity Duchenne® Trial ...
Deck Review with Regenxbio. Get these analyses to your inbox —… | by ...
At REGENXBIO, our industry-leading gene therapy Manufacturing ...
REGENXBIO’s Research and Development Facility, Maryland, US
Positive One-Year Results for REGENXBIO’s RGX-121 Strengthen Case Ahead ...
Regenxbio: RGX-314 Continues Advancing With Solid Financials (NASDAQ ...
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy | pharmaphorum
US FDA places clinical hold on Regenxbio's rare disease program | Reuters
REGENXBIO, Headquarters by EwingCole - Architizer
Person holding mobile phone with logo of American biotechnology company ...
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three ...
REGENXBIO’s Investor Conference Roadshow: A Catalyst for Gene Therapy ...
REGENXBIO’s ABBV-RGX-314 Trials Aim to Reduce Treatment Burden in ...
REGENXBIO: Transforming Gene Therapy With Innovative AAV Treatments ...
FDA extends review of Regenxbio's MPS II gene therapy to assess longer ...
Regenxbio发布wet AMD基因疗法RGX-314长效积极数据-和元生物
REGENXBIO's Strategic Momentum in Gene Therapy: Pipeline Visibility and ...
REGENXBIO's Q1 2025 Update: A Crucial Crossroads for Gene Therapy ...
REGENXBIO's Ixo-vec nAMD Gene Therapy Presentation Design | SlideGenius
REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority ...
.jpg?VersionId=brMmXv7v7FpVphkmBKUykqDPZvN_GYdj)
.jpg?VersionId=YA72pK01VHjww.YFKl.A45GrOcdHi1JD)
